Premature ejaculation is a male sexual dysfunction characterized by short, easily stimulated ejaculation that occurs always or nearly always before or within one minute of vaginal penetration.
It is involuntarily controlled and causes negative personal consequences like distress, frustration and avoidance of sexual intimacy.
Exact etiology and risk factors are unknown.
Short, easily stimulated ejaculation that occurs always or nearly always before or within about 1 minute of vaginal penetration or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less
Either present from the first sexual experience or following a new bothersome change in ejaculatory latency
Causes negative personal consequences eg distress, bother, frustration, avoidance of sexual intimacy and interpersonal difficulty
Most common male sexual dysfunction with prevalence not affected by age
More common in younger men
Unknown exact etiology with few data to support the following suggested biological and psychological hypotheses including:
5-HT receptor dysfunction
Risk factors include:
Genetic influences (lifelong PE)
Prostatic inflammation and chronic bacterial prostatitis (acquired PE)
Hormonal aberrations or thyroid hormone disorders
Poor overall health status and obesity
Psychological factors that may precipitate PE are historical
factors (eg sexual abuse, attitude towards sex in the home), individual
psychological factors (eg body image, depression, performance anxiety)
or relationship factors (eg intimacy, anger)
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.